Dermatology
Latest News
Topical delgocitinib shows promise for chronic hand eczema, pivotal trial shows
Delgocitinib is an investigational topical pan-JAK inhibitor that inhibits activation of the JAK-STAT pathway.
Latest News
Air pollution may be causing eczema
There are now more than three times as many eczema cases as there were in the 1970s, and it now affects as many as 20% of children and 10% of...
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Latest News
Anifrolumab shows promise in refractory discoid lupus erythematosus
Anifrolumab improved symptoms and activity of DLE within 2 months in a study of eight women.
Latest News
New data forecast more oral PDE4 inhibitors for psoriasis
The phase 2b data suggest that the drug, called orismilast, “is a potential new addition to the psoriasis armamentarium,” said Lars E. French, MD...
Conference Coverage
New JAK inhibitor study data confirm benefit in alopecia areata
Deuruxolitinib (CTP-543), an inhibitor of the JAK1 and JAK2 enzymes, has the potential to become the second JAK inhibitor available for the...
Latest News
Pilot study evaluates sensitive skin burden in persons of color
“We were particularly surprised by the high rates of reactivity to skin care products designed for and marketed to those suffering with sensitive...
Latest News
Expert shares her tips for diagnosing, treating onychomycosis
“We need to be antifungal stewards, because resistant dermatophytes are coming,” Dr. Boni E. Elewski said.
News from the FDA/CDC
Cases of potentially deadly fungus jump 200%: CDC
People in hospitals and nursing homes are at a heightened risk because they might have weakened immune systems or be using invasive medical...
Latest News
Phase 3 prurigo nodularis trial shows positive results for nemolizumab
“The use of topical steroids was not allowed in this trial,” Dr. Shawn G. Kwatra said.
Latest News
Novel therapy shows promise for treating skin-predominant dermatomyositis
The study drug “is a potent, selective humanized IgG1-neutralizing antibody directed at IFN-beta,” said Dr. Aaron Mangold, the principal...